`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`DAIICHI SANKYO, INC., DAIICHI
`SANKYO COMPANY, LIMITED, and
`ASTRAZENECA PHARMACEUTICALS LP,
`
`
`
`
`
`SEAGEN INC.,
`
`
`
`
`
`v.
`
`
`
`
`
`
`
`Plaintiffs,
`
`Defendant.
`
`
`
`
`
`
`C.A. No. 20-1524-LPS
`
`
`
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`
`
`
`
`JOINT STATUS REPORT
`
`Pursuant to the Court’s April 28, 2021 Order (D.I. 34), and further to their May 21, 2021
`
`and June 21, 2021 Joint Status Reports (D.I. 35, 36), the parties provide this update regarding the
`
`action pending in the Eastern District of Texas1 and Seagen Inc.’s (“Seagen’s”) patent at issue in
`
`the above-captioned action and the Texas case (“the ’039 patent”).
`
`On June 28, 2021, Judge Gilstrap denied Daiichi Sankyo, Inc.’s (“DSC”) Motion to
`
`Dismiss for Lack of Subject Matter Jurisdiction and Lack of Personal Jurisdiction and DSC’s
`
`Motion to Transfer Under 28 U.S.C. § 1404 to the District of Delaware, filed in the Texas case.
`
`Ex. A. Accordingly, Seagen’s patent infringement claims against DSC will not be transferred to
`
`this Court and shall proceed in accordance with the schedule in the Texas case (see Ex. A at 23).
`
`Furthermore, on June 24, 2021, the Patent Trial and Appeal Board declined to institute
`
`DSC’s and AstraZeneca Pharmaceuticals LP’s petitions for post-grant review of the ’039 patent.
`
`Exs. B-C. See also D.I. 32 at 8:1-4 (discussing pending petitions at oral argument on Seagen’s
`
`Motion to Stay or Dismiss). In addition, on July 16, Seagen dropped from the Texas case Claims
`
`
`1 Seagen Inc. v. Daiichi Sankyo Company, Limited, No. 2:20-337 (E.D. Tex.) (“Texas case”).
`
`
`
`Case 1:20-cv-01524-LPS Document 37 Filed 07/21/21 Page 2 of 3 PageID #: 846
`
`6-8 of the ’039 patent. Claims 6-8 of the ’039 patent remain pending in the above-captioned
`
`action.
`
` In light of the foregoing decisions, Seagen respectfully submits that the stay of this
`
`action, which currently expires on July 27, 2021, should be extended to remain in place until the
`
`final adjudication of or dismissal of the Texas case. Seagen further proposes that the parties
`
`submit a further Joint Status Report to this Court within ten (10) days of entry of final judgment
`
`or a dismissal of the Texas case.
`
`
`
`Plaintiffs, on the other hand, respectfully submit that the stay of this action, which
`
`currently expires on July 27, 2021, should be extended another 90 days to permit the parties to
`
`reach mutual agreement as to (1) the non-overlapping patent claims (Claims 6-8 of the ’039
`
`patent) and (2) whether the stay should be extended until the final adjudication of or dismissal of
`
`the Texas case.
`
`ASHBY & GEDDES
`
`
`/s/ Steven J. Balick
`
`
`
`
`Steven J. Balick (No. 2114)
`Andrew C. Mayo (No. 5207)
`500 Delaware Avenue, 8th Floor
`P.O. Box 1150
`Wilmington, Delaware 19899
`(302) 654-1888
`sbalick@ashbygeddes.com
`amayo@ashbygeddes.com
`Attorneys for Plaintiffs Daiichi
`Sankyo, Inc. and Daiichi
`Sankyo Company, Limited
`
`
`
`
`
`
`
`
`
`
`
`YOUNG CONAWAY STARGATT
`& TAYLOR, LLP
`
`/s/ Samantha G. Wilson
`
`
`
`
`Anne Shea Gaza (No. 4093)
`Samantha G. Wilson (No. 5816)
`Rodney Square
`1000 North King Street
`Wilmington, Delaware 19801
`(302) 571-6600
`agaza@ycst.com
`swilson@ycst.com
`
`Attorneys for Defendant
`
`
`
`2
`
`
`
`Case 1:20-cv-01524-LPS Document 37 Filed 07/21/21 Page 3 of 3 PageID #: 847
`
`
`
`MCCARTER & ENGLISH, LLP
`
`/s/ Alexandra M. Joyce
`
`
`
`
`Michael P. Kelly (No. 2295)
`Daniel M. Silver (No. 4758)
`Alexandra M. Joyce (No. 6423)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`mkelly@mccarter.com
`dsilver@mccarter.com
`ajoyce@mccarter.com
`Attorneys for Plaintiff
`AstraZeneca Pharmaceuticals LP
`
`Dated: July 21, 2021
`
`
`
`
`28390236.1
`
`
`
`3
`
`